US-based immuno-oncology company TapImmune launches its Phase II study of TPIV 200 to treat platinum-sensitive ovarian cancer patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The TPIV 200 is a multi-epitope folate receptor peptide vaccine that fights breast and ovarian cancer.

The product is composed of five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF).

The Phase II ovarian cancer study will be conducted as a double-blind, placebo controlled study intended to evaluate the benefits of using TPIV 200 in combination with standard of care chemotherapy.

TapImmune president and COO Dr John Bonfiglio said: "The opening of this study represents the fulfillment of a major 2016 milestone.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"We now have three clinical studies utilising TPIV 200 with approvals to enrol patients.

"The opening of this study represents the fulfillment of a major 2016 milestone."

“A fourth study in triple-negative breast cancer sponsored by the Mayo clinic with a $13.3m grant from the Department of Defence is scheduled to begin shortly.

“We believe the depth of these clinical programmes will give us an excellent understanding of how this exciting T-cell therapy can potentially be used in the treatment of both triple-negative breast and ovarian cancers."

According to the National Institute of Health, most patients with advanced ovarian cancer experience a recurrence of the disease within three years, with the initial recurrence generally being platinum-sensitive.

Platinum-sensitive recurrence describes the condition when the patient who experienced the relapse after chemotherapy can be administered with the same therapy to treat disease recurrence.

Image: TapImmune tests T-cell therapy to fight ovarian cancer. Photo: PRNewsFoto/TapImmune, Inc.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact